A lower "biological age" on an epigenetic clock does not reliably mean a person's health got better, according to a new systematic review of studies in people.
The review, published in Experimental Gerontology in 2026, is a systematic review. It pools no new participants. Instead, the authors searched for existing human studies of anti-aging interventions and compared what happened to epigenetic clocks with what happened to clinical outcomes. They included 26 independent studies: 13 comparative studies and 13 single-arm before-and-after studies. The abstract does not give the total number of participants.
Epigenetic clocks estimate biological age from chemical tags on DNA, called DNA methylation. Some companies and researchers report a clock score as a sign that aging has slowed or reversed. The question here was simple: when a clock changes after an intervention, do real health measures change with it?
Mostly, the answer was inconsistent. The authors classified each study by comparing its clock result with its clinical result. Fifteen studies were mixed. Six were indeterminate and four were jointly inconclusive. Only one study was uniformly concordant for intermediate outcomes, and it was an uncontrolled study. No comparative study was uniformly concordant. No study of patient-important outcomes was uniformly concordant either. Eleven studies went further. They looked at whether individual people's clock changes matched their own clinical changes, whether responders differed from non-responders, or whether the clock explained an intervention's effect. According to the authors, clear findings were isolated and were not replicated across independent studies.
The evidence was too varied to combine. No pairing of intervention, clock and clinical outcome met the criteria for a meta-analysis. The review also found no trial-level validation of a clock as a surrogate endpoint, which is a stand-in measure that can replace a harder outcome such as disease. The authors rated the certainty of evidence as very low across all the bodies of evidence they assessed.
The authors say favorable signals were concentrated mainly in selected intermediate outcomes. They conclude that epigenetic clocks should currently be considered exploratory or adjunctive biomarkers of intervention response, not validated clinical surrogate endpoints.
For the public, the practical meaning is about how to read claims. A change in a clock score, on its own, is not shown by this review to reflect a change in health. The review does not say clocks are useless, and it does not test any single product or program. Its abstract does not say why the results were inconsistent, so that remains open.
The finding fits with earlier coverage in The Arising. On October 20, we reported on a different systematic review that found no consistent epigenetic age reversal from antioxidant supplements. This review is a separate study, but it adds a related caution: the clock score is the thing being measured, and what it means for health is still unproven.
Trials that measure clocks and clinical outcomes together, with controls, and tests of whether clock changes explain health benefits. Readers should not start or stop any supplement, treatment or program without talking to their own clinician.
Sources: Experimental gerontology (2026), Experimental Gerontology
Read the cited source: Source 1
Keep reading on this subject
Biological-age clocks · Reading the evidence